THE CHALLENGE OF LIPID-MODIFYING THERAPIES IN THE ACHIEVEMENT OF OPTIMAL LDL-C LEVELS IN HIGH AND VERY HIGH CV RISK PATIENTS: STILL AN OPEN QUESTION

被引：0
|
作者：
Rossi, I. [1 ]
D'Ardes, D. [1 ]
Bucciarelli, B. [2 ]
Bianco, F. [3 ]
Troiano, F. [1 ]
Vizzarri, P. [1 ]
Caporale, M. [1 ]
Cipollone, F. [1 ]
Bucci, M. [1 ]
机构：
[1] Univ G dAnnunzio, Med & Aging Sci, Chieti, Italy
[2] Azienda Osped Univ Osped Riuniti, Pediat, Ancona, Italy
[3] Azienda Osped Univ Osped Riuniti, Cardiol, Ancona, Italy
来源：
ATHEROSCLEROSIS | 2022年 / 355卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
EP645
引用
收藏
页码：E306 / E306
页数：1
相关论文
共 47 条
  • [31] Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany
    Maerz, Winfried
    Dippel, Franz-Werner
    Theobald, Karlheinz
    Gorcyca, Katherine
    Iorga, Serban R.
    Ansell, David
    ATHEROSCLEROSIS, 2018, 268 : 99 - 107
  • [32] What is the potential cardiovascular risk reduction associated with achieving LDL-C levels recommended in the ESC/EAS guidelines for very high-risk patients? Data from 18 European countries
    Ray, K. K.
    Bray, S.
    Catapano, A. L.
    Poulter, N.
    Villa, G.
    EUROPEAN HEART JOURNAL, 2020, 41 : 3003 - 3003
  • [33] Lipid-modifying Effects of Anacetrapib in Patients with Lower versus Higher Baseline Levels Of HDL-C, LDL-C, And TG: Pre-Specified Subgroup Analyses of the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) Trial
    Brinton, Eliot
    Liu, Sherry
    Stepanavage, Michael
    Cannon, Christopher P.
    Davidson, Michael
    Gotto, Antonio M.
    Shah, Sukrut
    Dansky, Hayes
    Mitchel, Yale
    Barter, Philip
    CIRCULATION, 2011, 124 (21)
  • [34] Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease
    Toth, Peter P.
    Foody, JoAnne M.
    Tomassini, Joanne E.
    Sajjan, Shiva G.
    Ramey, Dena R.
    Neff, David R.
    Tershakovec, Andrew M.
    Hu, Henry
    Tunceli, Kaan
    JOURNAL OF CLINICAL LIPIDOLOGY, 2014, 8 (01) : 107 - 116
  • [35] Achievement of non-HDL-C and apo B goals in high-risk patients who achieve their Atp III LDL-C goal: Mercury II trial
    Ballantyne, CM
    Raichlen, JS
    Cain, VA
    Sager, PT
    ATHEROSCLEROSIS SUPPLEMENTS, 2005, 6 (01) : 101 - 101
  • [36] The effect of implementing a guideline-based approach to achieve target LDL-C levels in very high risk patients. The PENELOPE study one year follow-up results
    Van Der Brug, S. J.
    Khader, A. O.
    Atazadah, M.
    Liem, A. H.
    Groenemeijer, B. E.
    Schut, A.
    Martens, F. A. M.
    Dunselman, P. H. J. M.
    Alings, A. M. W.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [37] Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL-C
    Julius L. Katzmann
    Francesc Sorio-Vilela
    Eugen Dornstauder
    Uwe Fraas
    Timo Smieszek
    Sofia Zappacosta
    Ulrich Laufs
    Clinical Research in Cardiology, 2022, 111 : 243 - 252
  • [38] Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL-C
    Katzmann, Julius L.
    Sorio-Vilela, Francesc
    Dornstauder, Eugen
    Fraas, Uwe
    Smieszek, Timo
    Zappacosta, Sofia
    Laufs, Ulrich
    CLINICAL RESEARCH IN CARDIOLOGY, 2022, 111 (03) : 243 - 252
  • [39] Age, Abdominal Obesity, and Baseline hsCRP Are Associated with LDL-C, Non-HDL-C and ApoB Responses to Lipid-Lowering Therapy in Patients with Metabolic Syndrome and Moderately High/High CHD Risk
    Robinson, Jennifer G.
    Ballantyne, Christie M.
    Hsueh, Willa A.
    Rosen, Jeffrey B.
    Lin, Jianxin
    Shah, Arvind K.
    Tomassini, Joanne E.
    Lowe, Robert S.
    Tershakovec, Andrew M.
    DIABETES, 2011, 60 : A188 - A188
  • [40] Very high-risk familial hypercholesterolaemia patients in real life: The remaining gap in achieving the current LDL-C targets despite the use of PCSK9 inhibitors
    Rallidis, Loukianos S.
    Liberopoulos, Evangelos N.
    Vlachopoulos, Charalambos
    Skoumas, Ioannis
    Kolovou, Genovefa
    Anastasiou, Georgia
    Dima, Ioanna
    Tousoulis, Dimitrios
    Iliodromitis, Efstathios
    ATHEROSCLEROSIS, 2020, 309 : 67 - 69
12345